Thursday, July 9, 2026

Patent intelligence · US

US 10792363

Anhydrous sodium thiosulfate and formulations thereof

granted A61KA61K33/04A61K33/243A61K47/02
Status granted
Linked drugs 1
Pipeline programs 3
Years to expiry 14
Applicant portfolio 8
Patent details — US 10792363
Jurisdiction
US
Status
granted
Grant date
Oct 6, 2020
Expiration
Oct 1, 2040
Claims
27
CPC classes
A61K, A61K33/04, A61K33/243, A61K47/02
View on Google Patents ↗

Quick answer

US 10792363 (Anhydrous sodium thiosulfate and formulations thereof) is held by Fennec Pharmaceuticals, Inc.. Status: granted. Granted Oct 6, 2020. Expires Oct 1, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
27
CPC classes
A61K, A61K33/04, A61K33/243, A61K47/02, A61K47/18, A61K47/183

More from Fennec Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12311026

    Therapeutic uses for sodium thiosulfate formulations

    Fennec Pharmaceuticals, Inc. · Expires May 22, 2045

    granted
  2. US 11998604

    Therapeutic uses for sodium thiosulfate formulations

    Fennec Pharmaceuticals, Inc. · Expires May 30, 2044

    granted
  3. US 11992530

    Therapeutic uses for sodium thiosulfate and formulations

    Fennec Pharn ceuticals Inc. · Expires May 23, 2044

    granted
  4. US 11964018

    Therapeutic uses for sodium thiosulfate formulations

    Fennec Pharmaceuticals, Inc. · Expires Apr 18, 2044

    granted
  5. US 11617793

    Anhydrous sodium thiosulfate and formulations thereof

    Fennec Pharmaceuticals, Inc. · Expires Mar 30, 2043

    granted
  6. US 11510984

    Anhydrous sodium thiosulfate and formulations thereof

    Fennec Pharmaceuticals, Inc. · Expires Nov 24, 2042

    granted
  7. US 11291728

    Anhydrous sodium thiosulfate and formulations thereof

    Fennec Pharmaceuticals, Inc. · Expires Mar 31, 2042

    granted

Frequently asked questions

What is US patent 10792363?

US 10792363 (Anhydrous sodium thiosulfate and formulations thereof) is held by Fennec Pharmaceuticals, Inc.. Status: granted. Granted Oct 6, 2020. Expires Oct 1, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10792363?

Fennec Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.

When does US 10792363 expire?

Our index shows an expiration date of Oct 1, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.